Ipamorelin / CJC-1295
A paired secretagogue (a GHRH analog with a ghrelin-receptor agonist) that signals the pituitary.
What this compound is.
This is a pairing of two peptides that act on the pituitary through complementary routes: CJC-1295, a growth-hormone-releasing hormone analog, and Ipamorelin, a selective ghrelin-receptor agonist. Together they are studied for how two signals converge on the same gland.
Ipamorelin is described in the literature as comparatively selective — a property researchers have examined when studying growth-hormone signaling in isolation from other hormonal effects.
How it has been studied.
Neutral notes on how this compound has been studied. These are not claims of safety or effectiveness, and not medical advice.
Researched as a combination approach for studying the body's endogenous growth-hormone pathways.
Ipamorelin studied for its selectivity relative to earlier ghrelin-receptor agonists.
CJC-1295 studied for its extended duration of action within the GHRH class.
Format, and what a provider weighs.
Prescribed formulations are typically administered by subcutaneous injection. Form and suitability are a provider's decision — nothing here is a recommendation, a protocol, or a dose.
- A provider reviews your endocrine history, medications, and goals to determine whether either component is appropriate.
- Not appropriate during pregnancy or while breastfeeding.
- A combination is not inherently more suitable than a single agent — that judgment belongs to the provider.
Ipamorelin / CJC-1295 cannot be purchased directly on this site. It is available only after a licensed provider evaluates your intake and determines that treatment is clinically appropriate, and it is dispensed by a licensed compounding pharmacy. Eligibility is never guaranteed, and availability varies by state. See how it works and our approach to care.